MTM Laboratories has developed a proprietary technological platform that has identified a novel biomarker that serves for the early detection of cervical cancer. New diagnostics that detect the earliest stages of cancer are essential for improving its successful treatment, particularly since early cancer detection is critical for optimizing treatment regimens and maximizing medical treatment benefits. The company’s biomarker-based diagnostic test is able to diagnose cervical cancer even in pre-symptom stages, a major advance in the field of women’s health as early detection of the cancer greatly increases the prognosis of patients. With 140 million pap smears and 5 million cervical biopsies performed each year; both of which commonly yield inaccurate and inconclusive results, the company’s diagnostic test has significant market opportunity.
Categories: cancer, COMPANIES, Diagnostics, Technology Report
